High-dose methotrexate and asparaginase for the treatment of children with acute lymphoblastic leukemia: Why and how?

Journal of Pediatric Hematology/Oncology

Volumn 26, Issue 6, 2004, Pages 333-335

  Kamen, Barton A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY INACTIVATING ASPARAGINASE; ASPARAGINASE; CYTARABINE; DRUG ANTIBODY; FOLIC ACID; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; BRAIN LEUKEMIA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG EFFICACY; DRUG INACTIVATION; DRUG INDICATION; EDITORIAL; HUMAN; PRIORITY JOURNAL; SIDE EFFECT;

ANTINEOPLASTIC AGENTS; ASPARAGINASE; CHILD; HUMANS; LEUCOVORIN; LEUKEMIA, LYMPHOCYTIC, ACUTE; METHOTREXATE;

EID: 2942556711     PISSN: 10774114     EISSN: None     Source Type: Journal    
DOI: 10.1097/00043426-200406000-00001     Document Type: Editorial

References (27)

1. Cohen IJ. Defining the appropriate dose of folinic acid after high-dose methotrexate for childhood acute lymphoblastic leukemia that will prevent neurotoxicity without rescuing malignant cells in the central nervous system. J Pediatr Hematol Oncol. 2004;26:156-163.
2. Panosyan EH, Seibel NL, Martin-Argon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia. J Pedriatr Hematol Oncol. 2004.
3. Holcenberg J. Optimal Asparaginase Therapy. J Pediatr Hematol Oncol. 2004;26:273.
4. Lobel JS, O'Brien RT, McIntosh S, et al. Methotrexate and asparaginase combination chemotherapy in refractory acute lymphoblastic leukemia of childhood. Cancer. 1979;43:1089-1094.
5. Kamen BA, Cole P, Bertino JR. Chemotherapeutic agents: folic acid antagonists. In Holland JF, Frei E, Bast RC, et al, eds. Cancer Medicine. Philadelphia: Williams & Wilkins, 2003:727-738.
6. Clarke M, Gaynon P, Hann I, et al. CNS-directed therapy for childhood acute lymphoblastic leukemia: Childhood ALL Collaborative Group overview of 43 randomized trials. J Clin Oncol. 2003;21:1798-1809.
7. Abromowitch M, Ochs J, Pui CH, et al. Efficacy of high-dose methotrexate in childhood acute lymphoblastic leukemia: analysis by contemporary risk classifications. Blood. 1988;71:866-869,
8. Kamen BA, Winick NJ. High-dose methotrexate therapy: insecure rationale? Biochem Pharmacol. 1988;37:2713-2715.
9. Ackland SP, Schilsky RL. High-dose methotrexate: a critical reappraisal. J Clin Oncol. 1987;5:2017-2031.
10. Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy-a Pediatric Oncology Group study. J Clin Oncol. 1998;16: 1712-1722.
11. Sirotnak FM, Donsbach RC, Moccio DM, et al. Biochemical and pharmacokinetic effects of leucovorin after high-dose methotrexate in a murine leukemia model. Cancer Res. 1976;36:4679-4686.
12. Sirotnak FM, Moccio DM, Dorick DM. Optimization of high-dose methotrexate with leucovorin rescue therapy in the L1210 leukemia and sarcoma 180 murine tumor models. Cancer Res. 1978;38:345-353.
13. Browman GP, Goodyear MD, Levine MN, et al. Modulation of the antitumor effect of methotrexate by low-dose leucovorin in squamous cell head and neck cancer: a randomized placebo-controlled clinical trial. J Clin Oncol. 1990;8:203-208.
14. Kamen BA, Vietti T. Oral Leucovorin increases CSF folate concentration in children with leukemia. Br J Cancer. 1989;60:799.
15. Mahoney DH Jr, Shuster J, Nitschke R, et al. Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial. J Clin Oncol. 1998;1:246-254.
16. Kamen BA, Winick N, Holcenberg J. Oral vs IV MTX: another opinion. J Clin Oncol. 1998;16:2283-2284.
17. Goldin A, Venditti JM, Humphreys SR, et al. Modification of treatment schedules in the management of advanced mouse leukemia with amethopterin. J Natl Cancer Institute. 1956;17:203-212.
18. Skipper HE, Schabel FM, Mellet LB. Implications for biochemical, cytokinetic, pharmacologic and toxicologic relationships in the dosing of optimal therapeutic schedules. Cancer Chemother Rep. 1970;54:431-450.
19. Keefe D, Capizzi R, Rudnick S. Methotrexate cytotoxicity for L5178Y/Asn lymphoblasts: relationship of dose and duration of exposure to tumor cell viability. Cancer Res. 1982;42:1641-1645.
20. Hum M, Smith A, Lark R, et al. Evidence for negative feedback of extracellular methotrexate (MTX) on ALL blasts in vitro. Pharmacotherapy. 1997;17:1260-1266.
21. Pui CH, Schrappe M, Camitta B. Spotlight on long-term results of pediatric ALL clinical trials from 12 study groups world wide. Leukemia. 2000;14: 2193-2320.
22. Nachman JB, Sather HN, Sensel MG, et al. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998;338:1663-1671.
23. Winick N, Shuster JJ, Bowman WP, et al. Intensive oral methotrexate protects against lymphoid marrow relapse in childhood B-precursor acute lymphoblastic leukemia. J Clinical Oncology. 1996;14:2803-2811.
24. Harris MB, Shuster JJ, Pullen DJ, et al. Consolidation therapy with antimetabolite-based therapy in standard-risk acute lymphocytic leukemia of childhood: a Pediatric Oncology Group Study. J Clin Oncol. 1998;16: 2840-2847.
25. Lauer SJ, Shuster JJ, Mahoney DH Jr, et al. A comparison of early intensive methotrexate/mercaptopurine with early intensive alternating combination chemotherapy for high-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group phase III randomized trial. Leukemia. 2001;15:1038-1045.
26. Harris MB, Shuster JJ, Pullen J, et al. Treatment of children with early pre-B and pre-B acute lymphocytic leukemia with antimetabolite-based intensification regimens: a Pediatric Oncology Group study. Leukemia. 2000;14:1570-1576.
27. Mahoney DH Jr, Shuster JJ, Nitschke R, et al. Intensification with intermediate-dose intravenous methotrexate is effective therapy for children with lower-risk B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol. 2000;18:1285-1294.